Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong.
Hong Kong Med J. 2013 Feb;19(1):61-8.
OBJECTIVE; With the increasing use of biologics in patients with inflammatory bowel disease, the Hong Kong IBD Society developed a set of consensus statements intended to serve as local recommendations for clinicians about the appropriate use of biologics for treating inflammatory bowel disease.
The consensus meeting was held on 9 July 2011 in Hong Kong. Draft consensus statements were developed by core members of the Hong Kong IBD Society, including local gastroenterologists and colorectal surgeons experienced in managing patients with inflammatory bowel disease.
Published literature and conference proceedings on the use of biologics in management of inflammatory bowel disease, and guidelines and consensus issued by different international and regional societies on recommendations for biologics in inflammatory bowel disease patients were reviewed.
Four core members of the consensus group drafted 19 consensus statements through the modified Delphi process. The statements were first circulated among a clinical expert panel of 15 members for review and comments, and were finalised at the consensus meeting through a voting session. A consensus statement was accepted if at least 80% of the participants voted "accepted completely or "accepted with some reservation".
Nineteen consensus statements about inflammatory bowel disease were generated by the clinical expert panel meeting. The statements were divided into four parts which covered: (1) epidemiology of the disease in Hong Kong; (2) treatment of the disease with biologics; (3) screening and contra-indications pertaining to biologics; and (4) patient monitoring after use of biologics. The current statements are the first to describe the appropriate use of biologics in the management of inflammatory bowel disease in Hong Kong, with an aim to provide guidance for local clinical practice.
随着生物制剂在炎症性肠病患者中的应用日益增多，香港炎症性肠病学会制定了一套共识声明，旨在为临床医生提供关于生物制剂治疗炎症性肠病的适当使用的本地建议。
共识会议于 2011 年 7 月 9 日在香港举行。香港炎症性肠病学会的核心成员，包括在管理炎症性肠病患者方面经验丰富的本地胃肠病学家和结直肠外科医生，制定了共识草案。
对生物制剂在炎症性肠病管理中的应用的已发表文献和会议记录，以及不同国际和地区学会发布的关于炎症性肠病患者生物制剂建议的指南和共识进行了审查。
共识小组成员中的四位核心成员通过改良 Delphi 流程起草了 19 项共识声明。这些声明首先在一个由 15 名临床专家组成的小组中传阅，供他们审查和发表评论，然后在共识会议上通过投票程序最终确定。如果至少有 80%的参与者投票“完全接受”或“有保留地接受”，则可以接受一项共识声明。
临床专家小组会议产生了 19 项关于炎症性肠病的共识声明。这些声明分为四个部分，涵盖：（1）香港疾病的流行病学；（2）生物制剂治疗疾病；（3）生物制剂的筛查和禁忌症；（4）使用生物制剂后的患者监测。目前的声明是首次描述在香港管理炎症性肠病中适当使用生物制剂的声明，旨在为本地临床实践提供指导。
